Jason Samuelian, DO
- Language(s): English, Spanish
- College: Brigham Young University
- Internship: Banner Good Samaritan Medical Center
- Residency: Baylor College of Medicine
- Board Certification: American Board of Radiology
Dr. Jason Samuelian is a Board-certified Radiation Oncologist, with expertise in novel radiation techniques including Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), Stereotactic Radiosurgery (SRS), and Stereotactic Ablative Radiotherapy (SABR). He has a particular interest in using new and advanced treatment techniques to minimize side effects. He most enjoys spending time with his patients and developing relationships with them that last long beyond their cancer care.
Dr. Samuelian joined Arizona Center for Cancer Care in 2015. He earned his Bachelor of Science degree in Exercise Physiology from Brigham Young University, where he graduated cum laude. He earned his medical doctorate at Midwestern University in Glendale, where he was awarded the MICA Scholastic Award in 2008, and graduated with Honors in 2010. He completed an internal medicine internship at Banner Good Samaritan Medical Center, followed by residency training at the Baylor College of Medicine, where he also served as chief resident. In addition, Dr. Samuelian has completed two brachytherapy fellowships — at the MD Anderson Cancer Center and the Seattle Prostate Institute.
Dr. Samuelian is a member of the American Society of Therapeutic Radiation Oncology, American Brachytherapy Society, American College of Radiology, American College of Radiation Oncology, and the American Society of Clinical Oncology. He has been invited to serve on the ASCO Professional Development Committee. He currently serves as Chairman of the Cancer Committee at Banner Boswell Medical Center in Sun City, a program accredited by the Commission on Cancer (CoC).
Dr. Samuelian actively participates in cooperative group clinical trials. His research has been published in peer-reviewed medical journals, and he has presented at national meetings on SABR for COPD patients with early stage lung cancer, IMRT for the treatment of rectal cancer, and prostate cancer brachytherapy, among others.